和黄医药(00013)宣布凡瑞格拉替尼 (HMPL-453) 用于二线治疗肝内胆管癌的中国新药上市申请获受理并获纳入优先审评

智通财经2025-12-29

智通财经APP讯，和黄医药(00013)发布公告，凡瑞格拉替尼 (fanregratinib ，HMPL-453)用于既往接受过系统性治疗，且具有成纤维细胞生长因子受体(“FGFR”)2融合或重排的晚期、转移性或不可手术切除的肝内胆管癌(ICC)成人患者的新药上市申请已获中国国家药品监督管理局(“国家药监局”)受理，并获纳入优先审评。凡瑞格拉替尼是一种新型、选择性的FGFR1 、2和3口服抑制剂...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2595788714?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-29 16:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2595788714","market":"us","top_or_hot":-1,"title":"和黄医药(00013)宣布凡瑞格拉替尼 (HMPL-453) 用于二线治疗肝内胆管癌的中国新药上市申请获受理并获纳入优先审评","media":"智通财经","content":"<div>\n<p>智通财经APP讯，和黄医药(00013)发布公告，凡瑞格拉替尼 (fanregratinib ，HMPL-453)用于既往接受过系统性治疗，且具有成纤维细胞生长因子受体(“FGFR”)2融合或重排的晚期、转移性或不可手术切除的肝内胆管癌(ICC)成人患者的新药上市申请已获中国国家药品监督管理局(“国家药监局”)受理 ，并获纳入优先审评。凡瑞格拉替尼是一种新型、选择性的FGFR1 、2和3口服抑制剂...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1386500.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和黄医药(00013)宣布凡瑞格拉替尼 (HMPL-453) 用于二线治疗肝内胆管癌的中国新药上市申请获受理并获纳入优先审评</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黄医药(00013)宣布凡瑞格拉替尼 (HMPL-453) 用于二线治疗肝内胆管癌的中国新药上市申请获受理并获纳入优先审评\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-29 16:36 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1386500.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，和黄医药(00013)发布公告，凡瑞格拉替尼 (fanregratinib ，HMPL-453)用于既往接受过系统性治疗，且具有成纤维细胞生长因子受体(“FGFR”)2融合或重排的晚期、转移性或不可手术切除的肝内胆管癌(ICC)成人患者的新药上市申请已获中国国家药品监督管理局(“国家药监局”)受理 ，并获纳入优先审评。凡瑞格拉替尼是一种新型、选择性的FGFR1 、2和3口服抑制剂...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1386500.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1587","symbol_name":"次新股","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1386500.html","article_id":"2595788714","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2595788714","pubTimestamp":1766997386,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，和黄医药 发布公告，凡瑞格拉替尼 用于既往接受过系统性治疗，且具有成纤维细胞生长因子受体2融合或重排的晚期、转移性或不可手术切除的肝内胆管癌成人患者的新药上市申请已获中国国家药品监督管理局受理 ，并获纳入优先审评。凡瑞格拉替尼是一种新型、选择性的FGFR1 、2和3口服抑制剂。近年来，肝内胆管癌发病率呈持续上升趋势，5年总生存率约9%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1587":"次新股","00013":"和黄医药","BK1191":"制药","HCM":"和黄医药","BK1588":"回港中概股","BK4007":"制药","BK4531":"中概回港概念","BK4588":"碎股","BK4585":"ETF&股票定投概念"},"translate_title":"Chi-Med (00013) announced that the Chinese new drug marketing application for vanreglatinib (HMPL-453) for the second-line treatment of intrahepatic cholangiocarcinoma has been accepted and included in priority review","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HCM":1.5,"00013":1.5},"content_text":"智通财经APP讯，和黄医药(00013)发布公告，凡瑞格拉替尼 (fanregratinib ，HMPL-453)用于既往接受过系统性治疗，且具有成纤维细胞生长因子受体(“FGFR”)2融合或重排的晚期、转移性或不可手术切除的肝内胆管癌(ICC)成人患者的新药上市申请已获中国国家药品监督管理局(“国家药监局”)受理 ，并获纳入优先审评。凡瑞格拉替尼是一种新型、选择性的FGFR1 、2和3口服抑制剂。肝内胆管癌是一种起源于肝内胆管上皮的具有高度侵袭性的恶性肿瘤，占原发性肝癌的约8.2%至15.0% ，是继肝细胞癌之后第二常见的肝癌类型。近年来，肝内胆管癌发病率呈持续上升趋势，5年总生存率约9%。全球肝内胆管癌患者中约有10-15%伴有FGFR2融合或重排。一项在中国开展的单臂、多中心、开放标签的II期注册研究的数据支持了提交此项中国新药上市申请。该研究已达到客观缓解率(ORR)这一主要终点 。包括无进展生存期(PFS)、疾病控制率(DCR)、缓解持续时间(DoR)和总生存期(OS)在内的次要终点结果亦支持了主要终点的发现。完整的研究数据将于近期提交学术会议上发表。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2595788714","isCrawlerRequest":true}